| Identification | Back Directory | [Name]
SMND-309 | [CAS]
1065559-56-9 | [Synonyms]
SMND-309
SMND 309;SMND309
(2E)-2-[6-[(E)-2-Carboxyvinyl]-2,3-dihydroxyphenyl]-3-(3,4-dihydroxyphenyl)acrylic acid
Benzeneacetic acid, 6-[(1E)-2-carboxyethenyl]-α-[(3,4-dihydroxyphenyl)methylene]-2,3-dihydroxy-, (αE)- | [Molecular Formula]
C18H14O8 | [MOL File]
1065559-56-9.mol | [Molecular Weight]
358.3 |
| Chemical Properties | Back Directory | [Melting point ]
>400℃ | [Boiling point ]
667.1±55.0 °C(Predicted) | [density ]
1.655 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 3.7 mg/mL (10.33 mM) | [form ]
Solid | [pka]
3.20±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats[1][2]. | [in vivo]
SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue. SMND-309 also decreases the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment reduces the liver damage and the liver fibrosis grade. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver[1]. | Animal Model: | Male Sprague-Dawley rats (180-200 g) with carbon tetrachloride[1] | | Dosage: | 2.5 mg/kg, 5 mg/kg and 10 mg/kg | | Administration: |
Oral intragastric; once a day; for 4 weeks | | Result: | The antifibrotic mechanisms might be associated with its ability to suppress the expression of CTGF as well as scavenge lipid peroxidation products and increase endogenous antioxidant enzyme activity.
|
| [storage]
Store at -20°C | [References]
[1] Hou J, Tian J, Jiang W, Gao Y, Fu F.
Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis.
Eur J Pharmacol. 2011 Jan 10;650(1):390-5. DOI:10.1016/j.ejphar.2010.10.019
[2] Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J.
Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats.
Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23. DOI:10.1111/j.1742-7843.2009.00490.x
[3] Wang Y, Zhang J, Han M, et al. SMND-309 promotes neuron survival through the activation of the PI3K/Akt/CREB-signalling pathway. Pharm Biol. 2016;54(10):1982-1990. DOI:10.3109/13880209.2015.1137951 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|